HOME >> BIOLOGY >> NEWS
Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients

Results in Treatment of Hospital Patients with Complicated Skin Infections Reported in Clinical Therapeutics

Oklahoma City, OK An antibiotic, currently being tested in clinical trials, produced a 74 percent cure rate for hospitalized patients with possibly life-threatening, complicated skin and skin structure infections (cSSSI). Tigecycline, a candidate antibiotic drug, produced these promising results in a study led by Russell G. Postier, M.D., OU Physicians Chairman of Surgery and John A. Schilling Professor of Surgery at the University of Oklahoma College of Medicine.

"Tigecycline displayed promising efficacy against a wide spectrum bacteria commonly related to complicated skin infections, with an acceptable safety profile. These data warrant further investigation in blinded comparator clinical trials, said Postier, John A. Schilling Professor and chairman of surgery, OU Physicians and the study's principle investigator. Results of the multicenter, phase 2 will be published in the May 2004, issue of Clinical Therapeutics.

In the study, 85 percent of patients who received 50-milligram (mg) doses of tigecycline were cured at the end of their seven- to 14-day treatment, and 74 percent were cured at the test-of-cure visit (the study's primary outcome measure), about 21 days after their initial dose of tigecycline. Similarly, 78 percent of patients on the 25-mg doses were cured at the end of treatment, and 67 percent at the test-of-cure visit. The decline in rates directly resulted from patients receiving either additional antibiotics or surgery between the end of their treatments and their test-of-cure visits.

The 50 mg group also had a higher overall bacterial eradication rate at the end of therapy, 74 percent, than the 62 percent rate of the 25 mg group. At the test-of-cure visit, the rates were 70 and 56, respectively. Additionally, the trial used laboratory tests to document tigecycline activity against
'"/>

Contact: Jennifer Petra
jpetra@porternovelli.com
212-601-8110
Porter Novelli
23-May-2004


Page: 1 2 3

Related biology news :

1. Tigecycline - antibiotic evaluated in surveillance trial
2. AAAS US Presidential Candidates Forum
3. US Presidential Candidates Forum
4. Candidate genes found which may play a role in cancer progressing from non-invasive to invasive
5. UCSD And NIH Researchers Isolate Candidates For Genetic Basis Of Human Taste
6. New Tuberculosis Vaccine Candidate Developed: Improved Delivery Of Antigens By Current Vaccine BCG (Bacille Calmette-Gurin)
7. Candidate Regulator Of The Temporal Component Of Neurotransmitter Release Identified
8. Duke Researchers Discover Candidate Susceptibility Gene For Autoimmune Disease
9. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
10. Smart antibiotics may result from UCLA research
11. K-State researcher working to improve alternatives to equine antibiotics

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/4/2019)... , ... April 02, 2019 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... takes place at the Gaylord National Harbor Hotel, Oxon Hill, Maryland, on April ...
(Date:4/4/2019)... ... April 03, 2019 , ... R3 Stem Cell is now ... Centers of Excellence. R3 wants patients to feel secure when they make a ... from Centers that use inferior regenerative biologics, protocols or amounts, R3 provides a ...
(Date:3/29/2019)... ... March 28, 2019 , ... In the wake of ... entirely dedicated to Chinese biobanks was launched in July 2018, in an agreement ... Biobank Branch, China Medicinal Biotech Association (BBCMBA). The one-year pilot programme offered two ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... ... April 09, 2019 , ... Sonny Bar Lisa, or Sonny ... for approximately two months. After a series of diagnostics, an MRI was performed ... owner, Alison, researched the injury and found that VetStem Regenerative Cell Therapy ...
(Date:4/8/2019)... (PRWEB) , ... April 09, 2019 , ... ... disease, the innovative non-profit research center Chan Zuckerberg Biohub (CZ Biohub) has chosen ... of antibody repertoires is part of CZ Biohub’s efforts to establish new approaches ...
(Date:3/27/2019)... ... March 26, 2019 , ... A leader in the field ... to veterinarians across the United States and Canada since 2004. The primary indications ... tissue injuries in the dog, cat, and horse. Recently, VetStem teamed up ...
(Date:3/23/2019)... ... March 22, 2019 , ... ... LenS3 Multi-Angle Light Scattering (MALS) detector , offering a revolutionary approach for the ... polysaccharides, proteins, and biopolymers. A novel optical design, a unique cell-block assembly, and ...
Breaking Biology Technology:
Cached News: